Bacterial RNA polymerase — Drug Target

All drugs that target Bacterial RNA polymerase — marketed and clinical-stage. Includes 6 drug classes acting on this target.

Drug classes

Rifamycin antibiotic · Non-absorbed rifamycin antibiotic · Bacterial RNA polymerase inhibitor · Ansamycin antibiotic · Macrocyclic antibiotic · Antibiotic (rifamycin)

Marketed (7)

• Rifampicin Capsules · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Rifamycin antibiotic · Infectious Disease
  Rifampicin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.
• Rifaximin (drug) · Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji · Rifamycin antibiotic · Gastroenterology / Infectious Disease
  Rifaximin is a non-absorbed antibiotic that inhibits bacterial RNA polymerase to reduce pathogenic gut bacteria.
• rifampin IV · University of California, San Francisco · Rifamycin antibiotic · Infectious Disease
  Rifampin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.
• Rifaximin oral tablet · Yokohama City University · Rifamycin antibiotic · Gastroenterology / Infectious Disease
  Rifaximin is a non-absorbed antibiotic that inhibits bacterial RNA polymerase to reduce pathogenic gut bacteria.
• RIF · South China Children's Leukemia Group · Rifamycin antibiotic · Oncology (supportive care) / Infectious Disease
  RIF is a rifampicin-based antimicrobial agent used in pediatric leukemia supportive care to prevent or treat infections.
• Rifamycin-containing regimen · National Taiwan University Hospital · Rifamycin antibiotic · Infectious Disease
  Rifamycins inhibit bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.
• Rifaximin (XIFAXAN) · University of California, San Francisco · Non-absorbed rifamycin antibiotic · Gastroenterology / Infectious Disease
  Rifaximin is a non-absorbed antibiotic that inhibits bacterial RNA polymerase to reduce pathogenic gut bacteria without systemic absorption.

Phase 3 pipeline (7)

• Rifaximin SSD · Bausch Health Americas, Inc. · Rifamycin antibiotic · Gastroenterology
  Rifaximin SSD is a non-absorbed antibiotic that inhibits bacterial RNA polymerase to reduce pathogenic gut bacteria.
• High-dose rifampicin · Seoul National University Hospital · Rifamycin antibiotic · Infectious Disease
  High-dose rifampicin inhibits bacterial RNA polymerase to suppress mycobacterial growth and modulate immune responses.
• Placebo matched to Rifampin · Hamilton Health Sciences Corporation · Bacterial RNA polymerase inhibitor · Infectious Diseases
  Rifampin is a bacterial RNA polymerase inhibitor.
• Rifapentine (RPT) · Walter K. Kraft · Rifamycin antibiotic · Infectious Disease
  Rifapentine inhibits bacterial RNA polymerase, preventing transcription and killing or stopping the growth of mycobacteria.
• Rifamycin SV MMX · RedHill Biopharma Limited · Ansamycin antibiotic · Gastroenterology / Infectious Disease
  Rifamycin SV MMX is a modified-release antibiotic that targets bacterial RNA polymerase to inhibit bacterial protein synthesis, with enhanced delivery to the colon.
• OPT-80 · Astellas Pharma Inc · Macrocyclic antibiotic · Infectious Disease
  OPT-80 is a macrocyclic antibiotic that inhibits bacterial protein synthesis by binding to the bacterial ribosome.
• Optimised dose rifampicin · Radboud University Medical Center · Antibiotic (rifamycin) · Infectious Disease
  Optimised dose rifampicin inhibits bacterial RNA polymerase to suppress mycobacterial protein synthesis and growth.